FDA Approves Second Drug in BD Simplist

BD Simplist decreases number of steps in vial and syringe injection sequence

/ Author:  / Reviewed by: Joseph V. Madia, MD

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the US Food and Drug Administration (FDA) has approved the second drug to be offered in the recently launched BD Simplist™ line of ready-to-administer prefilled generic injectables.

BD Rx launched its first drug – BD Simplist™ Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine – on March 27, 2013. BD Simplist prefilled injectables are designed to help improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence, reducing the potential risk of medication error.

“After a successful launch of BD Simplist prefilled injectables, we’re excited to be coming out with a second drug that is commonly used by clinicians. This is just the beginning of our new line of prefilled injectable products,” said Mark Sebree, President, BD Rx.

The potential for medication error exists with every injection. Clinicians perform up to 20 steps in a traditional vial and syringe injection sequence. But with BD Simplist prefilled injectables, the injection sequence is reduced to approximately 12 steps, reducing the potential risk of medication error and allowing for more focus on the patient and less on injection preparation.

The company plans to launch 20 to 30 drugs in its BD Simplist line of products during the next few years and is targeting generic injectables in doses most commonly relied on by clinicians in both the hospital and surgical center settings.

Reviewed by: 
Review Date: 
April 24, 2013